Insmed (INSM)
(Delayed Data from NSDQ)
$56.85 USD
-0.32 (-0.56%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $56.86 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Insmed, Inc. [INSM]
Reports for Purchase
Showing records 101 - 113 ( 113 total )
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
FDA Removes Clinical Hold on ARIKACE, Q1:12 Call Tomorrow - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
EU CF Phase III Study Start Breathes Life into Insmed, while We Wait for FDA Response - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of April 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Q4:11 Update - Nine-Month Dog Toxicology Study Unlikely To Find Safety Concern - REITERATE OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense: March 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Hold Removed for ARIKACE in NTM Setting, Undervalued Opportunity in Serious Lung Infections
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Results - Details Trickle Out - FDA OK''s Phase III in CF in Parallel with Dog Safety Study
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
FDA Backtracks on Acceleration of NTM Program, Asks for a Phase II Trial-Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
FDA Requests Additional Tox Studies, Lowering Price Target to $9 from $15
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Insmed, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $15 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G